{"id":71,"date":"2020-04-22T08:25:51","date_gmt":"2020-04-22T08:25:51","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=71"},"modified":"2020-05-12T05:41:25","modified_gmt":"2020-05-12T05:41:25","slug":"09-april-2020-favipiravir-higher-clinical-recovery-rate-at-day-7","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/09-april-2020-favipiravir-higher-clinical-recovery-rate-at-day-7\/","title":{"rendered":"(09 April 2020) Favipiravir- Higher clinical recovery rate (day-7) seen in patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Favipiravir- A Potential Antiviral for COVID-19?<\/p>\n<p>https:\/\/www.jwatch.org\/na51293\/2020\/04\/09\/favipiravir-potential-antiviral-covid-19<\/p>\n<p class=\"\">Researchers review the evidence for testing various drugs in treating COVID-19. In an open-label trial in Shenzhen, China, of oral favipiravir (1600 mg twice daily for 1 day, then 600 mg twice daily) plus inhaled interferon, patients had median shedding of virus of 4 days and radiographic improvement was seen in 91% of favipiravir-interferon treated subjects.&nbsp; A prospective, multicenter, open-label, randomized trial in China comparing favipiravir with umifenovir (Arbidol), a membrane-fusion inhibitor active against influenza viruses, was recently reported (<a href=\"https:\/\/doi.org\/10.1101\/2020.03.17.20037432\">MedRxiv 2020 Mar 27; [e-pub]<\/a>). It demonstrated a higher clinical recovery rate at day 7 in those on favipiravir among moderately ill patients but not among mildly or severely ill patients.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Favipiravir- A Potential Antiviral for COVID-19? https:\/\/www.jwatch.org\/na51293\/2020\/04\/09\/favipiravir-potential-antiviral-covid-19 Researchers review the evidence for testing various drugs in treating COVID-19. In an open-label trial in Shenzhen, China, of oral favipiravir (1600 mg twice daily for 1 day, then 600 mg twice daily)&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/09-april-2020-favipiravir-higher-clinical-recovery-rate-at-day-7\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(09 April 2020) Favipiravir- Higher clinical recovery rate (day-7) seen in patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,11,1],"tags":[26],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/71"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=71"}],"version-history":[{"count":3,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/71\/revisions"}],"predecessor-version":[{"id":74,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/71\/revisions\/74"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=71"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=71"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=71"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}